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Forward genetic screens in somatic tissues
Development of cancer requires the accumulation of genetic and epigenetic changes that each confer a selective advantage to the cell at a specific stage of tumorigenesis. Identification of genes involved in tumorigenesis can be greatly facilitated by genetic screens for mutations contributing to tumour formation in model organisms such as the mouse. Success of such screens is dependent upon (a) a high rate of mutagenesis in order to achieve sufficient hits for oncogenic transformation and (b) easy identification of the mutated gene(s). Furthermore, the identified mutations should not be restricted to tumorigenesis in the organism used for the screen, but should ideally also be relevant to human cancers.
Slow transforming retroviruses can efficiently induce oncogenic mutations via insertion of the provirus into the genome, and these oncogenic mutations can be identified relatively easily by determining the insertion site of the provirus. Consequently, these viruses have been widely used in genetic screens for mutations involved in the onset of tumorigenesis in various model organisms.
Transforming retroviruses as tools for genetic screening
Oncogenic retroviruses can be divided into two classes: acute and slow transforming viruses. Acute transforming retroviruses induce polyclonal tumours within 2 to 3 weeks after infection of the host. Transformation by these viruses is mediated by the expression of viral oncogenes such as v-Abl in the Abelson Murine leukaemia Virus (reviewed in Shore et al., 2002) , and v-Myb from the avian myoblastosis virus (reviewed in Lipsick and Wang, 1999) , which are virally encoded oncogenic versions of normal cellular genes. In contrast, slow transforming retroviruses induce mono-or oligoclonal tumours with a longer latency of 3-12 months. Tumorigenesis caused by slow transforming retroviruses is not induced by the presence of a virally modified proto-oncogene in the virus but results from mutations caused by insertion of the proviral retrovirus into the host genome. Elements in the proviral genome that regulate the viral transcript also act in cis on cellular gene transcripts. Depending on whether the provirus integrates into or in the vicinity of genes, these elements can enhance or disrupt normal transcription and thus induce oncogenic mutations.
Retroviral infection of cells is dependent on the binding of viral envelope proteins to cell surface receptors. After incorporation of the provirus into the genome, cells will start producing viral envelope proteins and cell surface receptors become occupied with these proteins, thus inhibiting reinfection of the cell. Recombination of the viral sequences with endogenous viral sequences encoding envelope proteins gives rise to mutant viruses encoding envelope protein variants that utilize different receptors, and thus can reinfect an infected cell. Furthermore, many integrated proviruses appear to harbor defective envelope sequences allowing reinfection by the same virus. In this way, cells can undergo multiple rounds of viral infection and mutations can accumulate in one cell (reviewed in Mikkers and Berns, 2003) . The ability to induce multiple mutations in the same cell, combined with the fact that the proviral insertion site can be easily identified by amplification of the genomic sequences flanking the retroviral insertion (see below), makes slow retroviruses very suitable for genetic screens for oncogenic mutations.
Slow transforming retroviruses have been found to induce tumours in various organisms like cats (FeLV), birds (ALV and REV) and mice (murine leukaemia virus (MLV) and mouse mammary tumour virus (MMTV).
LTRs regulate viral transcription
Mutation of cellular genes by retroviral insertions is mediated by proviral elements that drive and regulate retroviral transcription. These elements are present in the Long Terminal Repeats (LTRs) located at each end of the provirus (Figure 1 ). The LTR is composed of thee parts: U3, which can be subdivided into an enhancer and promoter region, R, containing both the start and termination sites for transcription, and U5.
The promoter in the U3 of MLV contains sequences involved in recruitment of the basal transcription machinery such as a TATA box and GC-rich sequences (Graves et al., 1985) . The structure of the MLV enhancer region is more complex and contains binding sites for transcription factors, which positively affect transcription, such as Ets (Gunther and Graves, 1994) , NF1 (Reisman, 1990) and CBF (Sun et al., 1995) family members. Efficient viral replication will be restricted to those cellular environments that provide the various transcription factors required for high levels of viral transcription. Therefore, cell-type specificity of retroviruses is governed by the constitution of the viral LTR. This is exemplified by the tropism of Moloney MLV for T-and B-cells and the induction of predominantly myeloid leukaemia by the Graffi-type murine leukaemia viruses (Erkeland et al., 2003 (Erkeland et al., , 2004 . Substitution of MLV U3 enhancer sequences with Feline leukaemia Virus U3 sequences induces a different spectrum of insertion sites in lymphoma than wild-type MLV virus, indicating that enhancer sequences not only regulate cell-type specificity of viral replication but also determine the pattern of insertional activation by the provirus (Starkey et al., 1998; Johnson et al., 2005; Nielsen et al., 2005) .
Mutation of cellular genes by proviral insertions can be achieved in different ways and may result in enhanced transcript levels, chimeric transcripts or truncation of cellular gene transcripts. Alteration of cellular gene transcription is mediated by proviral elements that are involved in the transcriptional regulation of the provirus; in particular, elements present in the LTR and the splice donor sites normally used for splicing of subgenomic sized viral transcripts. In the following sections, the various ways in which retroviral insertions mutate cellular genes are discussed, using examples of oncogenes and tumour suppressors that have been identified in retroviral insertion mutagenesis screens.
Proviral insertions enhance expression of the c-Myc proto-oncogene
The activity of enhancers is not restricted to the most proximal promoter but can also augment the activity of promoters over large distances via chromatin loop interactions (reviewed in West and Fraser, 2005) . Thus, viral enhancers of integrated proviruses can affect many genes, explaining why the majority of mutations found in retroviral insertion mutagenesis screens are enhancer mutations resulting in elevated expression of cellular genes. Enhancer mutations are predominantly found upstream of genes in the antisense orientation or downstream in the sense orientation. This may be in order to prevent the positioning of the viral promoter between the enhancer in the 5 0 LTR and the cellular gene possibly, because the enhancer is only capable of acting bi-directionally on the most proximal promoters.
An alternative explanation may be that viral enhancers (5 0 or 3 0 ) only function when they are not transcribed. The later model is supported by results showing that in MMTV-induced tumours enhancer mutations were found downstream of genes with the provirus in the antisense orientation. In these cases, the 5 0 LTR was deleted and transcription of the cellular Figure 1 Genomic organization of a retroviral provirus. The provirus contains long terminal repeats (LTRs) at both ends. LTRs can be subdivided into three regions: U3, R and U5. U3 contains the enhancer and promoter sequences that drive viral transcription, the R domains encode the 5 0 capping sequences (5 0 cap) and the polyA (pA) signal. Gag, pro, pol and env encode the viral components required for the assembly of viral particles. The Splice donor (SD) and splice acceptor (SA) necessary for the formation of the subgenomic mRNAs (e.g. env mRNA) that encode different viral proteins are also indicated gene was augmented by the enhancer in the 3 0 LTR (Clausse et al., 1993) .
Overexpression of the c-Myc proto-oncogene is a frequently found oncogenic mutation in retrovirally induced tumours, and mainly induces haematopoietic tumours like erythroleukaemias and T-cell lymphomas (reviewed in Dudley et al., 2002) . Depending on the retrovirus, different strategies are employed to mutate this gene, for example, c-Myc is mutated by proviral insertions that lead to fusion transcripts in 80% of avian leucosis virus (ALV)-induced tumours (Rosenberg and Jolicoeur, 1997, see below) , whereas c-Myc is primarily mutated by enhancer mutations in MLVinduced tumours (Figure 2 ) (Corcoran et al., 1984; Cuypers et al., 1984; Selten et al., 1984) . Enhancer mutations as far as 270 kb 3 0 of the promoter region of cMyc can affect Myc transcription levels, illustrating that enhancer mutations can have long-range effects on cellular gene transcription (Lazo et al., 1990) .
The c-Myc gene is often found mutated or transcriptionally deregulated in a wide range of human tumours, and overexpression of c-Myc induces tumorigenesis in mice (reviewed by Pelengaris et al., 2002) . The onset of c-Myc-induced lymhomagenesis is greatly accelerated by inactivation of the p19
Arf -Mdm2-p53 pathway (Eischen et al., 1999; Jacobs et al., 1999b) , which induces apoptosis in response to high Myc levels (Zindy et al., 1998) . Indeed, Bmi-1, a repressor of the Cdkn2a locus encoding p19ARF and p16 INK4a (Jacobs et al., 1999a) , is often overexpressed as a result of proviral insertions in MLV-infected EmMyc-transgenic mice . Also, members of the Pim serine/ threonine kinase family and Gfi-1 have been identified in retroviral mutagenesis screens as strong collaborators with overexpressed c-Myc in lymphomagenesis : van der Lugt et al., 1995 Mikkers et al., 2002b) . Like Bmi-1, both the Pim kinases and the Gfi-1 transcription factor may have antiapoptotic activities (Grimes et al., 1996; Fox et al., 2003; Aho et al., 2004) , which indicates that reduction of apoptosis is an important requirement for lymphomagenesis of Myc-overexpressing cells.
Enhancement of N-myc and Pim-1 expression by removal of 3 0 sequences Proviral insertions in the 3 0 UTR-encoding region of the gene may remove regulatory or destabilizing motifs in mRNAs by termination of gene transcription by either the polyadenylation signal present or the antisense cryptic polyadenylation signal in the viral enhancer. This kind of mutations will increase the levels of truncated, but wild-type protein-encoding mRNA and subsequently lead to enhanced levels of wild-type protein.
Sense proviral insertions in the 3 0 -terminal exon of the Pim-1 gene remove a portion of the 3 0 UTR, which is thought to contain motifs that reduce mRNA stability (Figure 3) . Thus, loss of this region increases Pim-1 expression levels Selten et al. 1985; Domen et al., 1987) . Overexpression of the Pim-1 serine/ threonine kinase strongly collaborates with c-Myc activation in lymphomagenesis . In fact, combination of an EmMyc and an EmPim transgene resulted in the perinatal death of doubly transgenic mice caused by pre-B cell leukaemias . The genes encoding two other Pim serine/threonine kinases, Pim-2 and Pim-3, were identified as frequent MLV proviral insertion sites in 
EmMyc/Pim1
À/À and EmMyc/Pim-1 À/À /Pim-2 À/À mice, respectively, indicating that members of this family can functionally complement each other in tumorigenesis (van der Lugt et al., 1995; Mikkers et al., 2002b) . Pim proteins are most likely involved in growth factor and cytokine signaling. Gene disruption of Pim family members in mice results in mild haematopoietic proliferation defects (Mikkers et al., 2004 and references therein) . Pim proteins may also suppress apoptosis in haematopoietic cells via inactivation of the proapoptotic Bad protein (Fox et al., 2003; Aho et al., 2004) and cause genomic instability when overexpressed (Roh et al., 2003) . Interestingly, high levels of Pim-1 expression have also been found in prostate cancers that were induced by overexpression of human c-Myc in the murine prostate, indicating that Pim-1 can also collaborate with c-Myc in the induction of nonhaematopoietic malignancies (Ellwood-Yen et al., 2003) . Moreover, increased Pim-1 expression is also found in human prostate cancers and correlates significantly with measures of clinical outcome (Dhanasekaran et al., 2001) .
Activation of N-myc in MLV-induced leukaemias provides another example of oncogenic mutation of a cellular gene through removal of 3 0 UTR sequences . In a panel of 40 tumours, 15 tumours contained insertions in the N-myc gene, indicating that N-myc is a common target of MLVinsertions. Remarkably, all the insertions were found within 100 bp of the last exon of N-myc, which results in the removal of about 600 bp of the 3 0 UTR due to termination of gene transcription by the polyA signal in the 5 0 LTR. Tumours showed elevated levels of N-myc expression, suggesting that removal of the 3 0 UTR stabilizes the N-myc mRNA . N-myc has been found mutated or amplified in human malignancies like neuroblastoma, medulloblastoma and small cell lung cancers (Table 1) (reviewed by Nesbit et al., 1999) indicating that N-myc, like its family member c-Myc, is a human oncogene.
Promoter insertions in the oncogene Evi-1
Proviruses inserted in the promoter region of cellular genes may cause gene activation provided that they are inserted in the same transcriptional orientation as the gene. This separates the gene from its cellular promoter and places it under control of the viral promoters present in the 5 0 or 3 0 LTR. Read-through of the transcription machinery from the virus promoter, past the 3 0 LTR polyadenylation signal and into the cellular gene results in formation of chimeric transcripts (Herman and Coffin, 1986; Swain and Coffin, 1993 (Cullen et al., 1984; Westaway et al., 1984; Wotton et al., 2002) . Promoter insertions of the MLV provirus responsible for gene activation have been found in, for example, the LCK, N-Ras and E2a genes (Voronova et al., 1987; Martin-Hernandez et al., 2001; Mikkers et al., 2002a, b) . Perhaps more importantly, retroviral promoter insertions have been instrumental in the identification of Evi-1 (for ecotropic viral insertion site 1) as a potential oncogene both in mice and in humans ( Figure 4 ) (Morishita et al., 1988; Mucenski et al., 1988; reviewed in Hirai et al., 2001) . Evi-1 can act both as a positive and negative regulator of gene expression, however, so far, its function is not completely understood. Although it is hardly expressed in normal murine or human haematopoietic cells, elevated expression of Evi-1 is found in several haematopoietic malignancies and may even be involved in other tumour types (reviewed by Hirai et al., 2001) . The oncogenic effects of Evi-1 overexpression in lymphomagenesis have been attributed to its negative effect on terminal differentiation of haematopoietic cells via repression of transcription (Morishita et al., 1992; Kreider et al., 1993; Palmer et al., 2001) .
Translocations on chromosome 3 fusing the Evi-1 gene to the Runx1 (or AML-1) gene have been found in patients suffering from acute myeloid leukaemia. These translocations result in the production of a chimeric protein that can induce malignant transformation of haematopoietic cells (reviewed by Cameron and Neil, 2004; Mitani, 2004) . Runx1 is one of the three members of a family of transcription factors involved in regulation of normal development and tissue-specific gene expression, which all have been linked to haematopoietic malignancies in humans. Interestingly, the Runx1, 2 and 3 genes are also frequently found to be targeted by retroviral insertions resulting in enhanced transcription in retroviral mutagenesis screens (reviewed by Cameron and Neil, 2004) . Runx2 was originally identified as the gene targeted by insertions found in the til-1 region in CD-2 Myc transgenic mice (Stewart et al., 1997) , and Runx1 and Runx3 have also been shown to be mutated in CD-2 Myc transgenic mice by promoter and enhancer insertions, respectively Wotton et al., 2002) .
Targeting of tumour suppressors: the case of p53 and NF1
Proviruses that insert into a cellular gene can prematurely terminate the gene's transcript, either by using the polyadenylation signal of the LTR or by using a cryptic polyadenylation signal present in the antisense orientation of the virus. Premature termination may result in an mRNA encoding either a truncated, inactive or unstable mutant protein or in an active variant protein (discussed in the next section). Alternatively, landing of a provirus within a gene may induce aberrant splicing events, thereby abrogating gene function. (Futreal et al., 2004) . At the time of submission, of the 343 genes present in the Cancer Gene Census, 41 of these loci were also identified within the list of 358 common insertion sites present in the RTCGD http://RTCGD.ncifcrf.gov.
Viral integrations inactivating the p53 tumour suppressor have been found in erythroleukaemic cell lines derived from spleens from mice infected with Friend leukaemia virus (Mowat et al., 1985; Ben-David et al., 1988) . Insertions in the gene resulted in high expression of mutant proteins or in a complete absence of p53 mRNA, indicating that second copy of the p53 gene has also been mutated by proviral insertions or other mechanisms. (Mowat et al., 1985; Ben-David et al., 1988 , 1990 . In a similar fashion, the Neurofibromatosis-1 tumour suppressor gene, which encodes the neurofibromin GTP-ase activating protein, is found inactivated by proviral insertions of MLV and a murine AIDS virus-related endogenous virus (Cho et al., 1995; Largaespada et al., 1995) . A high percentage of cell lines derived from these tumours possessed insertions in both NF1 alleles, and expressed only truncated NF1 transcripts and no stable, full-length neurofibromin. The same results were obtained with cell lines derived from the MLV-induced tumours with a proviral insertion in only one of the NF1 alleles, indicating that the wt allele has become inactivated by other means in these cell lines .
Although other cases of gene disruption by viral insertions have been reported (e.g. by the Feline Immunodeficiency Virus, Beatty et al., 2002) , inactivating mutations represent a minority of the oncogenic mutations identified in insertion mutagenesis screens, because both gene copies of a tumour suppressor must become inactivated to abolish protein activity. However, this does not hold for insertions that induce haploinsufficiency, or inactivation of one allele while retaining a wild-type allele (reviewed by Cook and McCaw, 2000; Quon and Berns, 2001 ). To our knowledge, no data have been reported on proviral inactivation of haploinsufficient tumour suppressors; however, results from a genetic screen in zebrafish suggest that screens for haploinsufficient tumour suppressors may yield interesting results (Amsterdam et al., 2004) . In this paper, zebrafish were constructed to be heterozygous for recessive embryonic lethal mutations and screened for tumour development. Zebrafish heterozygous for ribosomal protein genes showed elevated cancer incidence, while tumours isolated from these heterozygous zebrafish did not show loss-of-heterozygosity or mutations in the second allele of the ribosomal genes. However, tumours expressed lower levels of the normal transcript than wt cells, indicating that reduced levels of ribosomal proteins may be oncogenic, and suggesting that these genes do not represent classic tumour-suppressors that require loss-of-heterozygosity but rather may act as haplo-insufficient tumour suppressors (Amsterdam et al., 2004) .
For tumours carrying hemizygously deleted tumour suppressors, the absence of detectable mutations in the second tumour suppressor allele has often been attributed to other inactivating mechanisms as, for example, epigenetic silencing. However, this may also indicate that these tumour suppressors show haplo-insufficient effects while retaining the wild-type allele. Therefore, many tumour suppressor genes that show haploinsufficient effects in tumorigenesis could still be Retroviral insertion mutagenesis screens may be very useful for identification of haplo-insufficient tumour suppressor genes, since it allows efficient identification of recurrent retroviral insertions within genes. However, to verify potential haplo-insufficient tumour suppressors, tumours with mutated tumour suppressors must be analysed to determine whether an intact second allele is producing wild-type transcripts.
Activation by protein truncation: Notch1 and Tpl-2
Transcript truncation by proviral insertions may also produce a functional protein with oncogenic properties by deletion of either NH 2 -or COOH-terminal domains. The proto-oncogene Notch1, which is mutated in many human T-cell acute lymphoblastic leukaemias (Ellisen et al., 1991; Weng et al., 2004) , has been identified as a recurrent insertion site in MLV-induced T-cell leukaemia (Girard et al., 1996) . Notch1 encodes a transmembrane receptor involved in normal T-cell development, which is cleaved upon binding of its ligand, thereby generating an intracellular Notch1 protein that translocates to the nucleus to activate transcription (reviewed by Radtke et al., 2004) . Proviral insertions result in two different classes of Notch mutants that closely mimic the effect of mutations that have been found in human TALLs (Girard et al., 1996; Hoemann et al., 2000; Weng et al., 2004) . Moreover, it has been shown that overexpression of one of the provirally induced mutations accelerates lymphomagenesis in cancer-predisposed mice (Feldman et al., 2000) .
Mutations in the Tpl2 gene in MLV-induced lymphoma provide another example of insertions creating a truncated oncogenic version of a cellular protein Patriotis et al., 1993; Mikkers et al., 2002a, b; . Tpl-2 encodes a MAP kinase kinase kinase that can activate the ERK, JNK and p38 MAPK pathways and is required for continuous upregulation of genes involved in innate immune responses (Dumitru et al., 2000; Eliopoulos et al., 2002) . Proviral insertions frequently mutate the Tpl-2 gene in MLV-induced lymphoma and always target the last intron of the gene resulting in strongly increased levels of Tpl-2 mRNA levels, most likely due to removal of destabilizing motifs in the 3 0 UTR ( Figure 5 ) (Ceci et al., 1997) . In addition, the insertions create a carboxyterminally truncated Tpl-2 that is dramatically more potent than its wild-type counterpart, because negative regulation of Tpl-2 kinase activity by binding of the NF-kB1 p105 protein to its C-terminal activity is abrogated (Beinke et al., 2003) . Overexpression in mice of this Cterminally deleted Tpl-2, but not of wild-type Tpl-2, produced large-cell lymphoblastic lymphomas of T-cell origin, thus showing that truncating mutants of Tpl-2 are oncogenic in vivo (Ceci et al., 1997) .
Advances in cloning of insertion sites
Recent technical developments have increased not only the number of insertion sites that can be cloned per tumour but also improved the speed, efficiency and reliability with which they are cloned. In the earliest screens, insertion sites were isolated and characterized Figure 5 Oncogenic truncation of Tpl-2 by proviral insertions. MLV insertions between the last two exons of the Tpl-2 gene (exons 7 and 8) terminate gene transcription and thus induce the formation of a truncated mRNA. The truncated mRNA encodes a mutant Tpl-2 protein with strongly increased kinase activity. The Tpl-2 gene consists of 7 coding (exons 2-8) and two noncoding exons (exons 1a and 1b). As depicted, splicing will incorporate either of the two noncoding exons in Tpl-2 mRNA. Exons are drawn as boxes (coding sequences in grey). The transcriptional and translational start site of the TpL-2 gene is indicated (horizontal arrow and ATG, respectively). The vertical arrow between exons 7 and 8 indicates the MLV insertion site by a combination of Southern blot analysis and genomic library screening (Hayward et al., 1981; Tsichlis et al., 1983; Corcoran et al., 1984; Cuypers et al., 1984; Selten et al., 1984) . Lambda libraries were constructed from tumour DNA and screened using viral sequences as probes. This approach was subsequently improved by engineering a tRNA amber suppressor selectable marker into the virus genome. The virus could then be used in combination with a lambda vector carrying amber mutations, to enrich libraries for virus encoding DNA fragments (Reik et al., 1985) . Once insertion sites had been identified within a tumour panel, these and other known proto-oncogene loci could then be screened in a more efficient manner, that is, by Southern blotting of tumour DNAs to detect insertions within these loci.
Over the past two decades, these strategies have been superceded by PCR-based methods that were developed for insertional screening in a range of organisms. These methods enrich for insertion site DNA by specifically amplifying sequences flanking the insertion site. One of these, inverse PCR, uses restriction digested DNA template, which has been ligated to itself at low concentrations to form circular templates. Those circles that contain the insertion sequence of interest are then preferentially amplified using primers, which point outward from the insertion sequence (Ochman et al., 1988; Triglia et al., 1988) (illustrated in Figure 6a ). Many different insertions can be amplified within the same reaction, although the products of inverse PCRs are limited to a 'window size' of fragments short enough to be efficiently PCRed but long enough to efficiently circularize. Dilution of the template before ligation can also result in inefficient amplification.
Linker mediated PCRs avoid the use of dilute, circular template DNA by instead using linkers ligated to the ends of digested DNA. A PCR is carried out with one primer against the insertion, and another against the linker. Numerous variants on this theme have been developed using different linkers: vectorette PCR (Riley et al., 1990; Arnold and Hodgson, 1991) , splinkerette PCR (Devon et al., 1995) , T-linker PCR (Yuanxin et al., 2003) and LAM-PCR (Schmidt et al., 2002; Hematti et al., 2004) . Each of these methods has its own strategy to avoid amplification of fragments that have linkers at both ends but no insert sequence (for an explanation of splinkerette PCR see Figure 6b ). Both inverse and linker mediated PCRs are dependent upon the presence of appropriate restriction sites close to the insertion site, hence both give improved coverage when employed using multiple restriction enzymes.
Methods that do not require ligation of template DNA have also been developed. Thermal Asymmetric Interlaced (TAIL) PCR enriches for target sequences Figure 6 Two PCR based methods of insertion site cloning. (a) Inverse PCR. Digested DNA is ligated into circles and insert specific primers pointing outward are used to amplify the regions external to the insertion site. (b) Splinkerette PCR. Digested DNA is ligated to a linker containing a noncomplementary hairpin at one end. In the first round of annealing and sythesis, only the viral primer is capable of binding a template. This newly synthesized strand is complementary to the linker top strand and in the second round of synthesis, the linker primer is able to anneal to the first strand synthesis. From this point onward amplification in exponential using a specific primer at one end and a degenerate primer at the other. Amplification occurs by alternating rounds of low, medium and high stringency (Liu and Whittier, 1995) . A similar approach using a combination of specific and degenerate primers (Sorensen et al., 1993; Sorensen et al., 1996) has been combined with a secondary step using specific biotinylated primers for enrichment of products on streptavidin beads.
While the above methods are all capable of amplifying small numbers of insertions per sample, not all are equally appropriate for MLV and MMTV induced tumours since these tumours may carry a large number of insertions of varying clonality. Ideally, methods for retroviral tumour screens should efficiently amplify multiple fragments, maintaining not only the complexity of the starting material but also the relative proportions of insertions from the starting DNA. Few if any studies have been published comparing different methods, but linker mediated approaches appear to dominate the recent literature. Further improvements in specificity and yield might also be achieved by combining different portions of the above methods or adapting some of these to use non-PCR methods of amplification (such as strand displacement amplification (SDA), rolling-circle amplification (RCA) and multiple-displacement amplification (MDA) (Walker et al., 1992; Lizardi et al., 1998; Dean et al., 2002) .
Fragment separation
Regardless of the strategy used, PCR fragments cannot be sequenced until they are separated from a mixture, usually on agarose or polyacrylamide gels. The eluted products are sequenced directly or following a reamplification step. Similarly sized fragments that comigrate on a gel cannot be separated from each other, thus multiple PCR templates prepared using different enzymes should be analysed for each tumour. This selective gel extraction has the advantage of enriching for sequences that represent the majority of the PCR, but as a consequence lacks the sensitivity required to find insertions that are either rare in the original DNA or else poorly PCR amplified. Gel extraction is also somewhat laborious and selection of fragments for elution introduces a subjective bias. Separation alternatives such as HPLC or capillary electrophoresis might be one way of increasing the throughput and reducing the bias of this approach.
Another approach to fragment separation is to subclone the PCR products directly into a vector, either by cloning gel eluted fragments or by shotgun subcloning the entire mixture (Suzuki et al., 2002; Johansson et al., 2004) . Plasmid DNA is isolated from single bacterial colonies and individual clones sequenced, thus allowing complex mixtures of fragments, including those of similar size, to be readily separated. With enough sequencing capacity, subcloning the entire mixture allows reproducible identification of sequences that represent only a tiny proportion of the PCR (our unpublished observations). Shotgun subcloning is also more amenable to automation than separation on gels, creating opportunities for increasing the scale and throughput of screens. Depending on the complexity of starting material, however, significant redundancy of sequencing may occur, thus more sequencing may be required to get the same level of coverage. Including a subcloning step might also introduce a bias against fragments that are not readily propagated in bacteria.
Other possible approaches
Different insertion sites could also be separated from each other during the PCR stage rather than after. Instead of using one or two PCRs to clone all insertions, amplification could be carried out by a larger series of separate PCRs, each of which only amplifies one of many potential templates. This might be achieved by using a series of restriction enzymes (or a single enzyme generating degenerate overhangs) to generate DNA fragments with different overhangs that can be ligated to a series of linkers with matching overhangs. Alternately, a series of PCR primers with primers that differ at their 3 0 end might be used to specifically amplify subsets of insertions independently from the same ligation mixture.
Non-PCR methods such as embedding selectable markers within the virus genome might eventually replace PCR-based enrichment. This approach has been successfully employed using the SupF marker to construct lambda libraries from tumour DNA (Reik et al., 1985) . Using markers that are selectable as plasmids rather than phage might allow a shotgun subcloning based-approach that skips the PCR stage. The concept of a plasmid-based shuttle vector is by no means novel (Cepko et al., 1984) ; however, its use for retroviral screens has been hindered by the fact that large inserts tend to interfere with replication competence of the virus. Even the 200bp tRNA amber suppressor fragment of the SupF virus has a tendency to be lost during in vivo viral replication. Presumably, the modified virus recombines with endogenous retroviruses, giving rise to non-tRNA carrying offspring strains that compete with the parent strain.
Replication defective viruses that express oncogenes are in some cases also capable of inducing tumours if they are transduced into haematopoietic precursors that are subsequently used to reconstitute depleted bone marrow (discussed later). Some replication defective strains have also been used to induce tumours by coinfection with a replication competent strain (Jaenisch, 1980; Johansson et al., 2004) . The replication competent strain acts as a 'helper' strain, although predictably the competent strain tends to dominate the resulting viremia in these animals, meaning that cloning insertions of the replication defective virus would only yield a subset of the total insertion sites. Alternately, propagating replication defective viruses in vivo might be achieved by transgenic expression of any or all of the viral gag pol and env transcripts, although it is perhaps difficult to predict how such transgenes might affect viremia kinetics and/or interact with endogenous retroviral like sequences.
Mapping and analysis
Improvements in techniques for insert cloning and sequencing has enabled studies which clone hundreds of insertion sites (Li et al., 1999; Hansen et al., 2000; Hwang et al., 2002; Joosten et al., 2002; Johansson et al., 2004; Suzuki et al., 2002; Mikkers et al., 2002a, b) . Mapping larger numbers of insertions is best handled by applications that have been optimized for finding high-quality matches for large numbers of sequences relatively rapidly such as BLAT (Kent, 2002) or SSAHA (Ning et al., 2001) . Once mapped the viral/genome junction is used to determine the exact position and orientation of proviral insertions. The precision with which individual sequences can be mapped varies, and is dependent upon the length of the PCR and quality of sequencing. Theoretically, fragments less than 20 base pairs can be mapped uniquely, in practice however, many high-quality longer sequences cannot be placed unambiguously because they map equally well to multiple repetitive elements throughout the genome.
The volume of data produced by some of these larger scale screens has prompted establishment of the Retroviral Tagged Cancer Gene Database (RTCGD, http:// RTCGD.ncifcrf.gov), containing a collection of miscellaneous retroviral insertion screens (Akagi et al., 2004) . At the time of its publication, this database contained approximately 3000 insertions derived from 1000 tumours, and this tally is periodically updated to include tumour sets from more recent publications. This resource not only creates the opportunity for multiple data sets to be analysed as one, but also facilitates comparison between screens conducted in different strains and genotypes. Many of these data sets have also been annotated onto the mouse genome browsers at UCSC (http://genome.ucsc.edu/ also linked from RTCGD) and also the Ensembl genome browser (http:// www.ensembl.org/Mus_musculus/) of the European Bioinformatics Institute and Wellcome Trust Sanger Institute.
There is, however, still potential for improvement of these resources. Insertion sites could be coupled with more thorough and comprehensive data from each tumour (such as detailed tumour histology, mouse characteristics, virus characteristics, literature of prior studies validating the locus). Global comparisons between different sets of insertions or specific searches using multiple tumour characteristics simultaneously might also be useful (for example, searching to compare the difference between insertions found in male and female mice with B-cell lymphomas on a wild-type background). Also mapping insertions to the syntenic regions of the human genome and coupling this information to the location of known human oncogenes should facilitate identification of which genes are affected by proviral insertion sites.
Defining common insertion sites
Common insertion sites (also called common integration sites or CISs) are loci that have been found to contain proviral insertions in multiple tumours. When insertions cloned from multiple independent tumours are found in the same locus, this overlap is unlikely to be due to chance but rather a result of selective expansion of tumour cells carrying insertions at this locus. If a moderate number of insertions were distributed randomly over the genome without any selection, it is unlikely that two or more insertions would occur within the vicinity of the same gene. As the number of insertions in a study increases, however, the chance that two insertions might be found within the same locus also increases. To date, the largest published sets of insertions number in the hundreds, and combining insertion sets from mutliple sources (as is done in the RTCGD), allows indentification of novel rare CISs and improves the resolution of known common insertion sites. However, with so many insertions, deciding whether a CIS might have occurred due to chance requires increasingly sophisticated statistical methods.
Parameters required for these analyses are genome size, the total number of insertions and the number of tumours from which they were derived. These parameters can be used to model a random distribution of insertions over the genome, and experimental deviations from this distribution can have a P-value attributed to them. However, these analyses are perhaps overly simplistic since they presume that retrovirus insertions will be randomly distributed throughout the genome prior to selection.
Measuring insertional biases
Discriminating CISs that have arisen by oncogenic selection from those representing insertional hotspots requires some knowledge of bias present in the starting population of insertions. Retroviruses, retrotransposons and transposons have all been shown to posess local and regional preferences for where they integrate in the genome (reviewed in Bushman, 2003) . At least some of these trends are thought to have evolved as a means of optimizing integration, expression, replication and/or excision.
Retroviral insertion biases have been estimated by a variety of methods. Early in vivo studies showed a preference of MLV for insertion close to DNAseI sensitive and/or hypomethylated regions (van der Putten et al., 1982; Vijaya et al., 1986; Rohdewohld et al., 1987) suggesting that oncogenic retroviruses had a tendency to insert within actively transcribed regions of the genome. More recently, high-throughput cloning of insertion sites from cell lines and primary tissues has examined insertion site preference with greater resolution. Insertions from MLV and HIV-1 infected cell lines (Schroder et al., 2002; Wu et al., 2003; Mitchell et al., 2004) and MLV and SIV infected primate haematopoietic precursors (Hematti et al., 2004) indicate that while both viruses preferentially insert into transcribed regions of the genome, MLV has a tendency to insert near gene promoters whereas lentiviruses integrate further downstream within transcriptional units. HIV-1 also appears to have a bias against CpG islands. By contrast, avian sarcoma-leukosis virus displays a weak preference for active genes and no preference for transcription start regions (Mitchell et al., 2004) .
These trends can be correlated with (and in some cases attributed to) the target DNA's local characteristics, including DNA sequence, conformation and methylation status, gene density, chromatin conformation, host DNA associated proteins and local transcriptional activity. For example, in vitro studies using Moloney MLV indicate that local DNA target availability is partially affected by nucleosome structure (Pryciak and Varmus, 1992) . Similarly, the preintegration complexes of mammalian retroviruses are known to associate with host expressed proteins such as mobility group protein A1 (HMG-A1), barrier-to-autointegration factor (BAF) and lamina-associated polypeptide 2 alpha (LAP2 alpha) (Li et al., 2000; Lin and Engelman, 2003; Suzuki et al., 2004) .
It seems likely that each combination of virus and host cell type will have its own unique insertional 'fingerprint' that can only be determined empirically by sequencing large numbers of independent unselected insertions. In the absence of this data, however, estimations could be based on each virus' known local insertion preferences extrapolated to the entire genome using information such as predicted gene boundaries, measurements of transcription levels, chromatin structure and distributions of chromatin associated proteins. Once a distribution pattern is measured and estimated, this could be used to adjust significance estimates of common insertion sites. Theoretical distributions used for modelling random insertions could then be modified to account for local background insertion density estimates, rather than estimates that presume random spread of insertions over the entire genome. Alternately, background insertion density could be used to define a minimum density threshold for common insertion sites to be considered significant.
Interpreting common insertion sites
Identifying which gene within a CIS is playing a causal role in oncogenesis is not simple, particularly in cases where expression of multiple genes is affected by an insertion (Hanlon et al., 2003) . Tumours harbouring common insertion sites are characterized initially by examining the expression and/or transcript size of candidate genes, and by verifying insert clonality by southern blot to see if the insertion is present within a substantial proportion of the tumour. In vitro assays for proliferation, apoptosis suppression, transformation, colony forming and anchorage independent growth can give an indication of a CIS candidate gene's role in oncogenesis, but ultimately the most convincing proof is the use of animal models of cancer, and/or by identification of functionally equivalent mutations in human cancers.
CIS interactions
Once CISs have been defined (either as loci or as specific genes), they can be correlated with other tumour characteristics such as host genotype, background strain, tumour histology and the presence or absence of other CISs within the same tumour. Tumours bearing a c-Myc insertion have a strong tendency to carry mutations in the Pim1, Gfi1, Ahi1/Myb, Rras2 and Cyclin D1 loci, suggesting the contribution of these loci toward tumorigenesis are complementary to c-Myc overexpression. Conversely, tumours carrying c-Myc insertions do not apppear to carry insertions within the Sox4, Hhex and Rasgrp1 loci. The significance of the cooccurrence of insertion sites can be verified using transgenic mice showing these genes collaborate in oncogenesis. Cooperation of c-Myc with Pim1 (van Verbeek et al., 1991) or Gfi-1 (Schmidt et al., 1998) has been demonstrated this way.
This phenomenon of insertion site cooperation has also been observed in a dramatic case of inadvertent insertional mutagenesis in humans. MLV infected AKxD mice have two known insertions in the LMO2 locus, one of which is associated with an insertion near the common gamma chain of the interleukin 2 receptor (IL2RG) (Dave et al., 2004) . A similar association has been observed between these genes during a gene therapy clinical trial for X-linked severe combined immunodeficiency (X-linked SCID). In this trial, a series of 10 infant X-SCID patients had their haematopoietic precursors infected with retroviral based gene therapy vector expressing the interleukin receptor common gamma chain (Hacein-Bey-Abina et al., 2002; Cavazzana-Calvo et al., 2005; Schmidt et al., 2005) . This treatment effectively cured nine of the 10 patients; however, within 3 years several of the patients were found to have developed T-cells leukaemia, where a copy of the retroviral vector had inserted near the LMO2 promoter (Marshall, 2003; Hacein-Bey-Abina et al., 2003a, b) . This case demonstrates the need for caution in the design of gene therapy vectors, but also suggests that the safety of such vectors might be testable using animal models.
One potential application for identifying novel oncogene interactions might be in finding candidates for development of cancer therapeutics. Mutation of the c-Myc oncogene is one of the most common events in human lymphoma and leukaemia, but it is currently not considered a druggable target. Loss of alleles of c-Myc collaborators such as the polycomb group protein Bmi1 or the kinase Pim-1 causes a delay in tumour onset induced by a c-Myc transgene and/or MLV (van der Lugt et al., 1995; Jacobs et al., 1999a, b) . By inference, if a c-Myc collaborator was found to be a druggable target, such a drug might have clinically useful effects on lymphomas that depend on c-Myc for disease progression. Conversely, if an oncogene found in retroviral screens is known to be a druggable target, identifying frequent collaborators may help in the profiling of patient tumour samples to determine which targeted therapeutics are appropriate, and may even suggest novel indications for existing therapies.
Using slow transforming retroviruses to generate other tumour types
The utility of slow transforming retroviruses for the study of cancer is limited by the range of tumours they induce. Deviations from MLVs propensity for Tlymphomagenesis can be induced by expression of oncogenic transgenes. The Emu-Myc transgene (c-Myc expressed from a CMV promoter/Emu enhancer) gives rise to lymphomas of a B-cell lineage and expands the pre-B-cell compartment (Adams et al., 1985; Langdon et al., 1986) . When these transgenics are infected with Moloney MLV, lymphomagenesis is accelerated and 90% of these lymphomas are B cell rather than the T cell lymphomas typical of Moloney MLV (Haupt et al., 1991; van Lohuizen et al., 1991) . MLVs can also be influenced by the background strain of the host, the recombinant inbred strain BXH-2 giving rise to myeloid leukaemias (Bedigian et al., 1984) and some AKxD strains showing a bias toward B-cell lymphomas (Gilbert et al., 1993) .
MLVs can also induce tumours in non lymphoid/ myeloid cell types by a combination of tissue specific virus delivery and viral driven oncogene expression (Uhrbom et al., 1998) . Tumours with the characteristics of human glioblastoma can be induced by expressing the platelet derived growth factor B-chain (PDGFB) from a replication incompetent Moloney MLV based retrovirus and delivering this virus to the brains of neonatal mice by intracerebral injection (Uhrbom et al., 1998; Johansson et al., 2004) . Autocrine activation of PDGF receptors is an important event in the genesis of human glioblastoma. Propagation of this PDGFB virus in vivo is enhanced by coinjection/coinfection with replication competent Moloney MLV. Cloning insertion sites from these tumours (using the LTR of both viruses) has identified loci known to be involved in human cancer as well as many previously identified from retrovirally induced leukaemias and lymphomas (Johansson et al., 2004) .
A similar strategy might also be employed using retroviruses that express short hairpin RNA inhibitors of tumour suppressor genes in combination with MLV based mutagenesis. Short hairpin RNAi retroviral vectors have been used for stable germline and somatic knockdown of gene expression (Rubinson et al., 2003) and can be targeted against tumour supressors to accellerate lymphoma development (Hemann et al., 2003) . The small size of siRNA transcripts might even allow development of replication competent viruses, eliminating the need for coinfection with helper strains.
Mutations of retroviral genomes (either spontaneously arising or artificially engineered) can also have a substantial influence on the tumour types that arise. This specificity is frequently attributable the LTR regions (DesGroseillers and Jolicoeur, 1984a, b) although in some cases subtle mutations can also alter the tropism of the virus envelope proteins (Bahrami et al., 2004) . A series of variants of the SL3-3 murine leukaemia virus that normally induces T-cell lymphomas have been shown to have altered oncogenic capabilities. A range of LTR mutations alter tumour latency (Ethelberg et al., 1997a, b; Ma et al., 2003) , alteration of SL3-3 enhancer factor 1 sites skews tumour formation away from thymic lymphoma (Hallberg et al., 1991) and mutation of Runx sites severely extends latency, inhibiting T-lymphomas and causing myeloid and to a lesser extent B-lymphoid and erythroid tumours (Sorensen et al., 2004) .
Manipulated viruses with reduced replication competence have a tendency to lose the changes made to them by recombination with related endogenous retrovirus like sequences. Thus, while it would seem there is untapped potential in the range of tumour types that manipulated slow transforming viruses can induce, the inherent tropism of these viruses and the limited replication competence and stability of manipulated viruses illustrates a need for alternate insertional mutagens to study other tumour types.
Transposable elements as insertional mutagens
Obvious candidates for developing novel insertional mutagens are transposable elements. These elements fall into two groups, those which use reverse transcriptase to transpose via an RNA intermediate and those which transpose in a 'cut and paste' manner as a DNA intermediate. Both types have been used as insertional mutagens in a range of organisms and recent developments have increased their utility in mammalian systems (for reviews see Hamer et al., 2001; .
Retrotransposons
Retrotransposons can be further subdivided into two main classes. The retroviral-like group possesses LTR and reverse transcriptase (although they encode no env protein) and their mode of replication and insertion is thought to be similar to retroviruses. The transcript is reverse transcribed and converted to ds DNA, and this fragment integrates into the genome, that is, reverse transcription and integration are separate events. The other group, known as Non-LTR retrotransposons or Poly(A) retrotransposons initiate reverse transcription from a single-strand break in recipient DNA which is used as a primer for the RNA transcript to be reverse transcribed. Thus, the reverse transcription event is coupled to integration.
Of this second group, long interspersed elements (LINEs) are the most prevalent in mammals, with LINE-1 (L1) elements comprising about 17% of the human genome. Recently, L1 elements have been investigated for their potential as germ line insertional mutagens in mammals (Ostertag et al., 2002) although the frequency of transposition events has been limited by the fact that endogenous L1 elements are inefficiently transcribed . Codon optimization of the L1 coding regions has removed this inhibition of transcription, resulting in increased L1 protein levels and a 200 fold increase in transposition activity . Whether this magnitude of increase will be sufficient for the use of L1 transposons as oncogenic somatic mutagens remains to be seen, however human L1 elements have recently been shown to be capable of mobilization in rodent neuronal precursor cells, in some cases altering gene expression and cell fate (Muotri et al., 2005) .
DNA Transposons
Transposable elements that move via a DNA intermediate (excising themselves from one site and integrating at another) have been used as insertional mutagens in plants, Drosophila and Caenorhabditis elegans. Most consist of transposase gene flanked by terminal inverted repeats. Some demonstrate a requirement for species specific host factors while others are active between species and in some cases between kingdoms (reviewed in Plasterk et al., 1999) . Endogenous cut and paste transposons have been found in vertebrates though most if not all appear to have degenerated due to loss of function mutations. This lack of active endogenous cut and paste transposons has prompted the engineering and enhancement of a number of elements for use in verterbrates. A number of Tc1/mariner family transposons have been shown to have activity in mammalian cells, including Tc1 and Tc3 from C. elegans, MosI from D. mauritania, Himar I from Haematobia irritans and Minos from D. hydei (reviewed in . Similarly the piggyBac DNA transposon of lepidopterans has been demonstrated to mobilize in human and mouse cell lines and in the mouse germ line (Ding et al., 2005) .
An alternative to adapting invertebrate transposons for use in vertebrates is to create synthetic transposons based on remnant degenerate transposon sequences found dispersed throughout vertebrate genomes. Sleeping Beauty (SB) is a synthetic transposon derived from ancient Tc1/mariner-like sequences of salmonid fish species. A consensus sequence was deduced from the inactive remnant transposon sequences of fish genomes, and a functional version was synthesized and named Sleeping Beauty 10 (SB10) (Ivics et al., 1997) . The newly awakened transposon was shown to be active not only in fish cells, but also human and mouse cells. More recently a similar approach has also been used to reconstruct 'Frog Prince', a related transposon from ancient Xenopus sequences (Miskey et al., 2003) .
The SB element consists of a transposon open reading frame flanked by inverted repeat/direct repeat (IR/DR) elements. The transposase protein functions as a tetramer, with a dimer binding each of the IR/DRs. Point mutations which increase transposition activity have been identified either by inference from related transposases or by alanine scanning substitutions (SB11 (Geurts et al., 2003) , SB12 (Zayed et al., 2004) , HSB1, HSB2, HSB3, HSB4 (Yant et al., 2004) ). Increase transposition frequency has also been achieved by specific point mutations (pT2 (Cui et al., 2002) ) or by direct replacement of the right IRDR with the left IRDR (pT3 (Yant et al., 2004) ).
These improvements in transposase activity and transposon mobility have increased the utility of SB for several applications. Nonviral gene therapy vectors based on SB have been developed and tested for somatic expression in mouse liver (Yant et al., 2000 (Yant et al., , 2002 and lung endothelial cells (Liu et al., 2004) . SB based vectors have been developed for transgenesis in zebrafish (Davidson et al., 2003) and Medaka (Grabher et al., 2003) . Germ line mutagenesis has also been attempted by coupling expression of the transposase with transgenes carrying a modified transposon (Fischer et al., 2001 ) and a gene trap transposon (Carlson et al., 2003) . A gene trap germ line mutagensis approach has also been developed in zebrafish (Clark et al., 2004) .
Two recent papers report successful use of SB as an oncogenic insertional mutagen in somatic tissues (Collier et al., 2005; Dupuy et al., 2005) . In both papers, an SB transposase transgene was expressed in mice, which also carry concatamers of gene trap transposons. These gene traps are designed to be activating and inactivating mutagens much like slow transforming retroviruses. They contain an MSCV promoter coupled to a FoxF2 splice donor in order to create fusion transcripts, which will drive expression of genes downstream of the insertion site. The transposons also contain splice acceptor sites coupled to a bidirectional SV40 polyadenylation signal, thus allowing for premature termination of transcripts running into the transposon. It is not yet known whether the IR/DR elements themselves might have transcriptional or enhancer activity on surrounding genes, although none has yet been reported.
In one of these papers (Collier et al., 2005 ) the SB10 transposase is expressed constitutively as a transgene driven by the CAGGs promoter. These mice do not develop tumours spontaneously; however, mobilization of the transposase appears to accelerate the onset of sarcomas in p19 ARF null mice. Insert analyses of these tumours reveal the presence of a prevalent common insertion site on chromosome 6 in the region of BRAF. These insertions create a truncated transcript, which while not equivalent to BRAF mutations seen in human melanoma , is nonetheless capable of inducing foci formation in NIH 3T3 cells.
In the other paper a more active version of the SB transposase, SB11, was integrated into the Rosa-26 locus. These mice were crossed onto a strain carrying close to 100 copies of a gene trap transposon. This combination of transposase and concatemer is apparently more potent since offspring of these crosses frequently die in utero, presumably because of the mutational load they are subject to during development. Those mice which survive until birth, succumb to cancer rapidly, in most cases of T-cell lymphomas but also medulloblastomas and some pituitary and intestinal neoplasias. A common insertion site was identified from the lymphomas, these insertions introducing truncation mutations of the Notch-1 transcript.
It remains to be seen the extent to which SB common insertion sites from haematopoietic and mammary tumours will either complement or substantially overlap with those induced by retroviruses. Transposons, like retroviruses, are not random in their integration, with specificity determined by host or element encoded factors (reviewed in Craig, 1997) . Several studies have examined the insertional biases of SB and found that it has a slight bias toward sites matching a consensus ATATATAT, and a preference for DNA with a bendable structure as well as several other specific conformational characteristics (Vigdal et al., 2002; Liu et al., 2005) . Cloning larger numbers of insertion sites from cell lines has also demonstrated a slight preference for integration within the promoters of genes, similar to MLV but less pronounced (Yant et al., 2005) . SB also demonstrated a strong bias toward microsatellite repeats, but no observable correlation with transcriptional activity.
When comparing this system to the use of slow transforming retroviruses the main advantage is its potential flexibility. The use of controlled tissue specific transposase expression should allow direction of tumorigenesis to nonlymphoid and nonmammary tissues. Altering the contents of the transposon (promoters, splice donors, splice acceptors, introns, RNA stability motifs, Kozak sequences) should also influence the types of mutations that can be created. Using different numbers of transposons will likely alter the extent to which individual insertions are selected for sequentially, or multiple cooperating insertions are selected together from the outset of tumorigenesis.
Screens based on DNA transposons are, however, prone to complications not present in retroviral screens. Excision of the SB transposon leaves behind 'foot print' mutations, thus transposons which hop more than once will contribute a background of mutations. Furthermore, insertion events, which are selected for and hence clonally expanded, are not immune to remobilization and may be lost in some cells during tumour growth. This could give rise to heterogenous tumours and may complicate analysis of insertion sites.
More troubling, however, is the observation that like other Tc1/mariner transposons, Sleeping Beauty has a strong preference for jumping in cis. This property complicates the analysis of CISs, with those occurring on the same chromosome as the donor concatamer needing to fulfil more stringent statistical criteria in order to be considered significant. The use of multiple mouse lines carrying concatamers on different chromosomes provides a simple solution to this problem; however, a means of distributing transposition events more evenly throughout the genome would improve the utility of this system.
Conclusion
A large number of the proto-oncogene and tumour suppressor loci found from retroviral screens have also been shown to be causally involved in human tumour development (Table 1 ). This provides some validation for the use of these screens to model human oncogenesis, and suggests that common insertion sites are useful candidates to pursue for mutation detection studies of human tumours. Even when equivalent mutations of CISs are not present in human tumours, understanding these CISs should still help clarify oncogenic branches of signaling networks and may even provide valuable targets for intervention downstream of mutated oncogenes.
As insertion site cloning methods improve and screens achieve greater saturation, this should allow better identification of not only oncogene gain of function mutations, but also rarer tumour suppressor and haploinsufficient tumour suppressor loss of function mutations. Screening of nonhaematopoietic tissues will be particularly valuable for the study of tumour types who's genetic aetiology is still poorly understood. Thus, although the principle of retroviral insertion mutagenesis has been around for quite a while now, its future holds promise.
